Skip to main
ASRT

ASRT Stock Forecast & Price Target

ASRT Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Assertio Hldgs is well-positioned for growth in the pharmaceutical industry due to its diverse and differentiated product portfolio, with a particular focus on the high-demand oncology market. The company's strong commercial capabilities allow it to effectively market and sell its products, leading to steady revenue growth and strong financial performance. As a result, the positive outlook for Assertio Hldgs is supported by its reliable revenue streams and potential for continued expansion in the future.

Bears say

Assertio Hldgs is in a significant shift phase, as it recently agreed to be acquired by Garda Therapeutics for $18 per share. This is a 34.6% premium to the company's unaffected stock price on March 20, 2026, and a 46.6% premium to the 30-day unaffected volume-weighted average price (VWAP). The deal was unanimously approved by both companies' boards, with the potential for a CVR tied to future milestones for a legacy product with low revenue potential. Due to this significant shift and limited upside potential, the analyst downgraded their rating on the stock to Neutral with a revised price target of $18 per share.

ASRT has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Assertio Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Assertio Therapeutics Inc (ASRT) Forecast

Analysts have given ASRT a Hold based on their latest research and market trends.

According to 2 analysts, ASRT has a Hold consensus rating as of Jul 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.65, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.65, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Assertio Therapeutics Inc (ASRT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.